• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种用于双特异性抗体和双价靶向抗体药物偶联物的小型化、无偏高通量筛选的通用方法。

A Generic Approach for Miniaturized Unbiased High-Throughput Screens of Bispecific Antibodies and Biparatopic Antibody-Drug Conjugates.

机构信息

Protein and Cell Sciences, EMD Serono, 45A Middlesex Turnpike, Billerica, MA 01821, USA.

NBE Technologies, Merck Healthcare KGaA, Frankfurter Str. 250, 64293 Darmstadt, Germany.

出版信息

Int J Mol Sci. 2024 Feb 8;25(4):2097. doi: 10.3390/ijms25042097.

DOI:10.3390/ijms25042097
PMID:38396776
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10889805/
Abstract

The toolbox of modern antibody engineering allows the design of versatile novel functionalities exceeding nature's repertoire. Many bispecific antibodies comprise heterodimeric Fc portions recently validated through the approval of several bispecific biotherapeutics. While heterodimerization methodologies have been established for low-throughput large-scale production, few approaches exist to overcome the bottleneck of large combinatorial screening efforts that are essential for the identification of the best possible bispecific antibody. This report presents a novel, robust and miniaturized heterodimerization process based on controlled Fab-arm exchange (cFAE), which is applicable to a variety of heterodimeric formats and compatible with automated high-throughput screens. Proof of applicability was shown for two therapeutic molecule classes and two relevant functional screening read-outs. First, the miniaturized production of biparatopic anti-c-MET antibody-drug conjugates served as a proof of concept for their applicability in cytotoxic screenings on tumor cells with different target expression levels. Second, the automated workflow enabled a large unbiased combinatorial screening of biparatopic antibodies and the identification of hits mediating potent c-MET degradation. The presented workflow utilizes standard equipment and may serve as a facile, efficient and robust method for the discovery of innovative therapeutic agents in many laboratories worldwide.

摘要

现代抗体工程的工具包允许设计超越自然范围的多功能新型功能。许多双特异性抗体包含最近通过批准几种双特异性生物疗法验证的异二聚体 Fc 部分。虽然已经建立了用于低通量大规模生产的异二聚化方法,但很少有方法可以克服大规模组合筛选的瓶颈,这对于识别最佳双特异性抗体至关重要。本报告介绍了一种新颖、稳健和小型化的基于可控 Fab 臂交换 (cFAE) 的异二聚化工艺,该工艺适用于多种异二聚体格式,并与自动化高通量筛选兼容。两种治疗分子类别和两种相关功能筛选读出证明了适用性。首先,双价抗 c-MET 抗体药物偶联物的小型化生产可作为其在具有不同靶表达水平的肿瘤细胞上进行细胞毒性筛选的概念验证。其次,自动化工作流程能够对双价抗体进行大规模无偏组合筛选,并鉴定出介导有效 c-MET 降解的命中。所提出的工作流程利用标准设备,可作为全球许多实验室发现创新治疗剂的简便、高效和稳健方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b10d/10889805/127a41549ae6/ijms-25-02097-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b10d/10889805/cbc766a3030b/ijms-25-02097-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b10d/10889805/bed146d2e776/ijms-25-02097-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b10d/10889805/b8b515a1afe6/ijms-25-02097-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b10d/10889805/127a41549ae6/ijms-25-02097-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b10d/10889805/cbc766a3030b/ijms-25-02097-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b10d/10889805/bed146d2e776/ijms-25-02097-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b10d/10889805/b8b515a1afe6/ijms-25-02097-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b10d/10889805/127a41549ae6/ijms-25-02097-g004.jpg

相似文献

1
A Generic Approach for Miniaturized Unbiased High-Throughput Screens of Bispecific Antibodies and Biparatopic Antibody-Drug Conjugates.一种用于双特异性抗体和双价靶向抗体药物偶联物的小型化、无偏高通量筛选的通用方法。
Int J Mol Sci. 2024 Feb 8;25(4):2097. doi: 10.3390/ijms25042097.
2
Greatest Hits-Innovative Technologies for High Throughput Identification of Bispecific Antibodies.高产量双特异性抗体高通量鉴定的创新技术
Int J Mol Sci. 2020 Sep 8;21(18):6551. doi: 10.3390/ijms21186551.
3
Biparatopic antibodies: therapeutic applications and prospects.双靶向抗体:治疗应用与前景。
MAbs. 2024 Jan-Dec;16(1):2310890. doi: 10.1080/19420862.2024.2310890. Epub 2024 Mar 4.
4
Bispecific Antibodies and Antibody-Drug Conjugates for Cancer Therapy: Technological Considerations.双特异性抗体和抗体药物偶联物在癌症治疗中的应用:技术考虑因素。
Biomolecules. 2020 Feb 26;10(3):360. doi: 10.3390/biom10030360.
5
Intein mediated high throughput screening for bispecific antibodies.内含肽介导的双特异性抗体高通量筛选。
MAbs. 2020 Jan-Dec;12(1):1731938. doi: 10.1080/19420862.2020.1731938.
6
Tethered-variable CL bispecific IgG: an antibody platform for rapid bispecific antibody screening.拴系可变CL双特异性IgG:一种用于快速双特异性抗体筛选的抗体平台。
Protein Eng Des Sel. 2017 Sep 1;30(9):627-637. doi: 10.1093/protein/gzx034.
7
Beyond bispecificity: Controlled Fab arm exchange for the generation of antibodies with multiple specificities.超越双特异性:控制 Fab 臂交换生成具有多种特异性的抗体。
MAbs. 2022 Jan-Dec;14(1):2018960. doi: 10.1080/19420862.2021.2018960.
8
A novel efficient bispecific antibody format, combining a conventional antigen-binding fragment with a single domain antibody, avoids potential heavy-light chain mis-pairing.一种新型高效双特异性抗体形式,将传统抗原结合片段与单域抗体相结合,避免了潜在的重轻链错配。
J Immunol Methods. 2020 Aug;483:112811. doi: 10.1016/j.jim.2020.112811. Epub 2020 Jun 19.
9
A biparatopic agonistic antibody that mimics fibroblast growth factor 21 ligand activity.一种双靶向激动性抗体,模拟成纤维细胞生长因子 21 配体活性。
J Biol Chem. 2018 Apr 20;293(16):5909-5919. doi: 10.1074/jbc.RA118.001752. Epub 2018 Feb 26.
10
Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies.克服双特异性异二聚体 IgG 抗体中链关联问题的进展。
MAbs. 2012 Nov-Dec;4(6):653-63. doi: 10.4161/mabs.21379. Epub 2012 Aug 27.

引用本文的文献

1
Enhancing NK cell-mediated tumor killing of B7-H6 cells with bispecific antibodies targeting allosteric sites of NKp30.利用靶向NKp30变构位点的双特异性抗体增强NK细胞介导的对B7-H6细胞的肿瘤杀伤作用。
Mol Ther Oncol. 2024 Dec 6;33(1):200917. doi: 10.1016/j.omton.2024.200917. eCollection 2025 Mar 20.
2
Advancements in mammalian display technology for therapeutic antibody development and beyond: current landscape, challenges, and future prospects.哺乳动物展示技术在治疗性抗体开发及其他领域的进展:现状、挑战与未来展望。
Front Immunol. 2024 Sep 24;15:1469329. doi: 10.3389/fimmu.2024.1469329. eCollection 2024.

本文引用的文献

1
Engineering hydrophobicity and manufacturability for optimized biparatopic antibody-drug conjugates targeting c-MET.为优化针对 c-MET 的双价靶向抗体药物偶联物的工程疏水性和可制造性。
MAbs. 2024 Jan-Dec;16(1):2302386. doi: 10.1080/19420862.2024.2302386. Epub 2024 Jan 12.
2
Mammalian display to secretion switchable libraries for antibody preselection and high throughput functional screening.哺乳动物分泌开关文库用于抗体预选和高通量功能筛选。
MAbs. 2023 Jan-Dec;15(1):2251190. doi: 10.1080/19420862.2023.2251190.
3
Glofitamab: First Approval.
格罗菲妥单抗:美国首次批准
Drugs. 2023 Jul;83(10):935-941. doi: 10.1007/s40265-023-01894-5.
4
A high throughput bispecific antibody discovery pipeline.高通量双特异性抗体发现管道。
Commun Biol. 2023 Apr 7;6(1):380. doi: 10.1038/s42003-023-04746-w.
5
Cell surface protein aggregation triggers endocytosis to maintain plasma membrane proteostasis.细胞膜表面蛋白聚集触发内吞作用以维持质膜蛋白稳态。
Nat Commun. 2023 Feb 28;14(1):947. doi: 10.1038/s41467-023-36496-y.
6
Current landscape and future directions of bispecific antibodies in cancer immunotherapy.双特异性抗体在癌症免疫治疗中的现状和未来方向。
Front Immunol. 2022 Oct 28;13:1035276. doi: 10.3389/fimmu.2022.1035276. eCollection 2022.
7
Antibodies as drugs-a Keystone Symposia report.抗体类药物——一个 Keystone 研讨会报告
Ann N Y Acad Sci. 2023 Jan;1519(1):153-166. doi: 10.1111/nyas.14915. Epub 2022 Nov 16.
8
Teclistamab: First Approval.特卡昔单抗:首次批准。
Drugs. 2022 Nov;82(16):1613-1619. doi: 10.1007/s40265-022-01793-1.
9
Preclinical Study of a Biparatopic METxMET Antibody-Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC.一种双靶点 METxMET 抗体药物偶联物,REGN5093-M114 的临床前研究,克服了 EGFR 突变 NSCLC 中 MET 驱动的获得性对 EGFR TKI 的耐药性。
Clin Cancer Res. 2023 Jan 4;29(1):221-232. doi: 10.1158/1078-0432.CCR-22-2180.
10
Mosunetuzumab: First Approval.莫舒替尼单抗:首次批准。
Drugs. 2022 Jul;82(11):1229-1234. doi: 10.1007/s40265-022-01749-5.